{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:41:04Z","timestamp":1784943664170,"version":"3.55.0"},"reference-count":21,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health and Medical Research Council postgraduate scholarship funding programme"},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli Lilly"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Merck Sharp and Dohme\/Schering Plough Joint Venture"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart Asia"],"accepted":{"date-parts":[[2018,11,1]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To ascertain the use of secondary prevention medications and cardiac rehabilitation after an acute coronary syndrome (ACS) and the impact on 2-year outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>CONCORDANCE (Cooperative National Registry of Acute Coronary care, Guideline Adherence and Clinical Events) is a prospective, observational registry of 41 Australian hospitals. A representative sample of 6859 patients with an ACS and 6 months\u2019 follow-up on 31 May 2016 were included. The main outcome measure was use of \u226575% of indicated medications (\u22654\/5 (or \u22653\/4 if contraindicated) of angiotensin-converting enzyme (ACE) inhibitor\/angiotensin receptor blocker, beta-blocker, lipid-lowering therapy, aspirin and other antiplatelet). Major adverse cardiovascular events (MACE) included myocardial infarction, stroke or cardiovascular death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mean age was 65\u00b113 years, 29% were women, and the mean Global Registry of Acute Coronary Events (GRACE) score was 106\u00b130. At discharge, 92% were on aspirin, 93% lipid-lowering therapy, 78% beta-blocker, 74% ACE\/angiotensin receptor blocker and 73% a second antiplatelet; 89% were taking \u226575% of medications at discharge, 78% at 6 months and 66% at 2 years. At 6 months, 38% attended cardiac rehabilitation, 58% received dietary advice and 32% of smokers reported quitting. Among 1896 patients followed to 2 years, death\/MACE was less frequent among patients on \u226575%\u2009vs &lt;75% of medications (8.3% vs 13.9%; adjusted OR 0.75, 95 % CI 0.56 to 0.99), and was less frequent in patients who attended versus who did not attend cardiac rehabilitation (4.6% vs 13.4%; adjusted OR 0.44, 95%\u2009CI 0.31 to 0.62).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Use of secondary prevention therapies diminishes over time following an ACS. Patients receiving secondary prevention had decreased rates of death and MACE at 2 years.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartasia-2018-011122","type":"journal-article","created":{"date-parts":[[2019,1,13]],"date-time":"2019-01-13T04:45:15Z","timestamp":1547354715000},"page":"e011122","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Secondary prevention therapies in acute coronary syndrome and relation to outcomes: observational study"],"prefix":"10.1136","volume":"11","author":[{"given":"Clara K","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadarajah","family":"Kangaharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karice K","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Briffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,1,12]]},"reference":[{"key":"2025090722553912000_11.1.e011122.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.111.964700"},{"key":"2025090722553912000_11.1.e011122.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7336.S71"},{"key":"2025090722553912000_11.1.e011122.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.24.2340"},{"key":"2025090722553912000_11.1.e011122.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14739-3"},{"key":"2025090722553912000_11.1.e011122.5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-9-200511010-00010"},{"key":"2025090722553912000_11.1.e011122.6","doi-asserted-by":"publisher","DOI":"10.1097\/HJR.0b013e328013f11a"},{"key":"2025090722553912000_11.1.e011122.7","doi-asserted-by":"publisher","DOI":"10.1097\/HJR.0b013e3283383f30"},{"key":"2025090722553912000_11.1.e011122.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61215-4"},{"key":"2025090722553912000_11.1.e011122.9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5694\/j.1326-5377.2010.tb03502.x","article-title":"Cardiovascular risk perception and evidence\u2013practice gaps in Australian general practice (the AusHEART study)","volume":"192","author":"Heeley","year":"2010","journal-title":"Med J Aust"},{"key":"2025090722553912000_11.1.e011122.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2012.12.013"},{"key":"2025090722553912000_11.1.e011122.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38985.646481.55"},{"key":"2025090722553912000_11.1.e011122.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.03.019"},{"key":"2025090722553912000_11.1.e011122.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007786","article-title":"Clinical characteristics, management and 1-year outcomes of patients with acute coronary syndrome in Iran: the Iranian Project for Assessment of Coronary Events 2 (IPACE2)","volume":"5","author":"Kassaian","year":"2015","journal-title":"BMJ Open"},{"key":"2025090722553912000_11.1.e011122.14","doi-asserted-by":"publisher","DOI":"10.1177\/1741826710389401"},{"key":"2025090722553912000_11.1.e011122.15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.gheart.2015.11.003","article-title":"Time trends in lifestyle, risk factor control, and use of evidence-based medications in patients with coronary heart disease in Europe: results from 3 EUROASPIRE surveys, 1999-2013","volume":"12","author":"Kotseva","year":"2017","journal-title":"Glob Heart"},{"key":"2025090722553912000_11.1.e011122.16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2025090722553912000_11.1.e011122.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2009.06.001"},{"key":"2025090722553912000_11.1.e011122.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10945"},{"key":"2025090722553912000_11.1.e011122.19","doi-asserted-by":"publisher","DOI":"10.1097\/HJR.0b013e32833cca66"},{"key":"2025090722553912000_11.1.e011122.20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/2047487317695616","article-title":"Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk","volume":"24","author":"Lafeber","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"2025090722553912000_11.1.e011122.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39570.749884.BE"}],"container-title":["Heart Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartasia-2018-011122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:55:51Z","timestamp":1757310951000},"score":1,"resource":{"primary":{"URL":"https:\/\/heartasia.bmj.com\/lookup\/doi\/10.1136\/heartasia-2018-011122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,12]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/heartasia-2018-011122"],"URL":"https:\/\/doi.org\/10.1136\/heartasia-2018-011122","relation":{},"ISSN":["1759-1104"],"issn-type":[{"value":"1759-1104","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}